DOCSLIB.ORG

Substance Use Disorders (Sud)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Substance Use Disorders (Sud) Clinical Practice Guideline Management of Substance Use Disorder s (SUD) August, 2009 VA/DoD Evidence Based Practice VA/DoD CLINICAL PRACTICE GUIDELINE FOR MANAGEMENT OF SUBSTANCE USE DISORDERS (SUD) Department of Veterans Affairs Department of Defense Prepared by: The Management of Substance Use Disorders Working Group With support from: The Office of Quality and Performance, VA, Washington, DC & Quality Management Office, United States Army MEDCOM QUALIFYING STATEMENTS The Department of Veterans Affairs (VA) and The Department of Defense (DoD) guidelines are based on the best information available at the time of publication. They are designed to provide information and assist in decision-making. They are not intended to define a standard of care and should not be construed as one. Also, they should not be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when providers take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in any particular clinical situation. Version 2.0 – 2009 Table of Contents Page Introduction 1 Guideline Update Working Group 4 Definitions 6 Algorithms and Annotations 8 Module A: Screening and Initial Assessment for Substance Use 10 Module B: Management of SUD in Specialty SUD Care 24 Module C: Management of SUD in (Primary) General Healthcare 39 Module P: Addiction‐Focused Pharmacotherapy 54 Module S: Stabilization and Withdrawal Management 74 Appendices Appendix A: Guideline Development Process 91 Appendix B: Screening and Assessment Tools 98 Appendix C: Addiction‐Focused Psychosocial Interventions 122 Appendix D: Department of Defense Instruction (DoDI 1010.6) 133 Appendix E: Sedative‐Hypnotic Equivalent Oral Doses 135 Appendix F: Acronym List 136 Appendix G: Participant List 137 Appendix H: Bibliography 142 VA/DoD Clinical Practice Guideline For Management of Substance Use Disorders INTRODUCTION The Clinical Practice Guideline for the Management of Substance Use Disorders (SUD) was developed under the auspices of the Veterans Health Administration (VHA) and the Department of Defense (DoD) pursuant to directives from the Department of Veterans Affairs (VA). VHA and DoD define clinical practice guidelines as: “Recommendations for the performance or exclusion of specific procedures or services derived through a rigorous methodological approach that includes: • Determination of appropriate criteria such as effectiveness, efficacy, population benefit, or patient satisfaction; and • Literature review to determine the strength of the evidence in relation to these criteria.” The intent of the guideline is to: • Reduce current practice variation and provide facilities with a structured framework to help improve patient outcomes • Provide evidence-based recommendations to assist providers and their patients in the decision-making process for patients with SUD • Identify outcome measures to support the development of practice-based evidence that can ultimately be used to improve clinical guidelines. BACKGROUND Substance use disorders (SUD) constitute a major public health problem with a substantial impact on health, societal costs, and personal consequences. • SUD in the VA population: In 2007 fiscal year, over 375,000 VA patients had a substance use disorder diagnosis and nearly 500,000 additional patients had a nicotine dependence diagnosis in the absence of other substance use disorders. (Dalton A, Saweikis M, McKellar JD: Health Services for VA Substance Use Disorder Patients: Comparison of Utilization Fiscal Years 2005, 2004, 2003 and 2002. Palo Alto, CA, Program Evaluation and Resource Center, 2004.) • SUD in the DoD population: The substantial negative consequences of alcohol use on the work performance, health, and social relationships of military personnel have been a continuing concern assessed in DoD surveys. In 2005, 8.1 percent of military personnel anonymously responding to a survey reported one or more serious consequences associated with alcohol use during the year, a decline from 9.6 percent in 2002. Using AUDIT criteria, 2.9 percent of respondents were estimated to be highly likely to be dependent on alcohol in 2005. (Bray RM, Hourani LL, Olmsted KLR, et al. 2005 Department of Defense Survey of Health Related Behaviors Among Active Duty Military Personnel. Research Triangle Park, NC: Research Triangle International, December, 2006.) Available at: http://www.ha.osd.mil/special_reports/2005_Health_Behaviors_Survey_1-07.pdf Target population This guideline applies to adult patients with substance use conditions treated in any VA/DoD clinical setting, including patients who have both substance use and other health conditions; and patients with any level of severity ranging from hazardous and problematic use to substance use disorders. Introduction - Page 1 VA/DoD Clinical Practice Guideline For Management of Substance Use Disorders Audiences The guideline is relevant to all healthcare professionals providing or directing treatment services to patients with substance use conditions in any VA/DoD healthcare setting, including specialty SUD care, and both general and mental healthcare settings. Goals of the Guideline • To identify patients with substance use conditions, including at-risk use, substance use problems and substance use disorders • To promote early engagement and retention of patients with substance use conditions who can benefit from treatment • To improve outcomes for patients with substance use conditions (cessation or reduction of substance use, reduction in occurrence and severity of relapse, improved psychological and social functioning and quality of life, improved co-occurring medical and health conditions and reduction in mortality). Content of the Guideline The guideline consists of five modules that address inter-related aspects of care for patients with SUDs. Module A: Screening and Initial Assessment for Substance Use includes screening, brief intervention, and specialty referral considerations. Module B: Management of SUD in Specialty SUD Care focuses on patients in need of further assessment or motivational enhancement or who are seeking remission. Module C: Management of SUD in General Healthcare (including primary care) emphasizes earlier intervention for less severe SUD, or chronic disease management for patients unwilling or unable to engage in treatment in specialty SUD care or not yet ready to abstain. Module P: Addiction-Focused Pharmacotherapy addresses use of medication approved by the Food and Drug Administration for the treatment of alcohol and opioid dependence. Module S: Stabilization and Withdrawal Management addresses withdrawal management including pharmacological management of withdrawal symptoms. Each module consists of an algorithm that describes the step-by-step process of the clinical decision- making and intervention that should occur in the specified group of patients. General and specific recommendations for each step in the algorithm are included in the annotations following the algorithm. The links to these recommendations are embedded in the relevant specific steps in the algorithm. Each annotation includes a brief discussion of the research supporting the recommendations and the rationale behind the grading of the evidence and the determination of the strength of the recommendations. Related Guideines Tobacco use should be addressed in all patients and is a major cause of morbidity and mortality among patients with non-nicotine SUDs. For management of nicotine dependence, refer to the Clinical Practice Guideline: Treating Tobacco Use & Dependence: 2008 Update from the U.S. Department of Health and Human Services available at: http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf and the VA/DoD Clinical Practice Guideline for Management of Tobacco Use. Introduction - Page 2 VA/DoD Clinical Practice Guideline For Management of Substance Use Disorders For management of patients presenting with SUDs and depression, refer to the VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (MDD). For management of prescribed opioids for chronic pain, refer to the VA/DoD Clinical Practice Guideline for the Management of Chronic Opioid Therapy. Additional recommendations for patients with co-occurring conditions may be found in the VA/DoD Clinical Practice Guideline for the Management of Post Traumatic Stress (ASD and PTSD). Development Process The development process of this guideline follows a systematic approach described in “Guideline-for- Guideline,” an internal working document of VA/DoD Evidence-Based Practice Working Group. The literature was critically analyzed and evidence was graded using a standardized format. The evidence rating system for this document is based on the system used by the U.S. Preventative Services Task Force (see Appendix A – Development Process). If evidence exists, the discussion of the recommendations includes an evidence table that indentifies the studies that have been considered, the quality of the evidence, and the rating of the strength of the recommendation [SR]. The strength of recommendation, based on the level of the evidence and graded using the USPSTF rating system (see Table: Evidence Rating System), is presented in brackets following each guideline recommendation. Recommendations that are
Load more

Recommended publications
  • Mnemonics in a Mnutshell: 32 Aids to Psychiatric Diagnosis
    Mnemonics in a mnutshell: 32 aids to psychiatric diagnosis Clever, irreverent, or amusing, a mnemonic you remember is a lifelong learning tool ® Dowden Health Media rom SIG: E CAPS to CAGE and WWHHHHIMPS, mnemonics help practitioners and trainees recall Fimportant lists (suchCopyright as criteriaFor for depression,personal use only screening questions for alcoholism, or life-threatening causes of delirium, respectively). Mnemonics’ effi cacy rests on the principle that grouped information is easi- er to remember than individual points of data. Not everyone loves mnemonics, but recollecting diagnostic criteria is useful in clinical practice and research, on board examinations, and for insurance reimbursement. Thus, tools that assist in recalling di- agnostic criteria have a role in psychiatric practice and IMAGES teaching. JUPITER In this article, we present 32 mnemonics to help cli- © nicians diagnose: • affective disorders (Box 1, page 28)1,2 Jason P. Caplan, MD Assistant clinical professor of psychiatry • anxiety disorders (Box 2, page 29)3-6 Creighton University School of Medicine 7,8 • medication adverse effects (Box 3, page 29) Omaha, NE • personality disorders (Box 4, page 30)9-11 Chief of psychiatry • addiction disorders (Box 5, page 32)12,13 St. Joseph’s Hospital and Medical Center Phoenix, AZ • causes of delirium (Box 6, page 32).14 We also discuss how mnemonics improve one’s Theodore A. Stern, MD Professor of psychiatry memory, based on the principles of learning theory. Harvard Medical School Chief, psychiatric consultation service Massachusetts General Hospital How mnemonics work Boston, MA A mnemonic—from the Greek word “mnemonikos” (“of memory”)—links new data with previously learned information.
    [Show full text]
  • Substance Abuse and Dependence
    9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine.
    [Show full text]
  • Title: Approved Behavioral Health Screening Tools for 3Ai and 4Aiii
    Title: Approved Behavioral Health Screening Tools for 3ai and 4aiii Date Created: 10/8/2015 Date Modified: 07/27/2017 Date Approved by Board of Directors: 11/10/2015 Clinical Guideline # CGC-CG-26 Purpose: The purpose of this guideline is to establish a menu of approved behavioral health screening tools for use in the 3ai Integration of Behavioral Health and Primary Care (Model 1) project and 4aiii Strengthening Mental Health and Substance Abuse Infrastructure Across Systems. Participating practices may choose from the menu of approved screening tools below or use nationally-accepted best practice that are determined to be aged-appropriate: Approved Screening Tools: Depression: PHQ-9: Patient Health Questionnaire (9 questions) PHQ-2: Patient Health Questionnaire (2 questions) Anxiety: GAD-7: General Anxiety Disorder (7 questions) Substance CAGE-AID: Cut-down, Annoyed, Guilty, and Eye-Opener (4 questions) Abuse: CAGE: 4 questions AUDIT: Alcohol Use Disorder Identification Test (10 questions) DAST- 10: Drug-Abuse Screening Test (10 question; excludes alcohol) CRAFFT: Series of 6 questions to identify adolescents 14- 21 years of age for risky alcohol and other drug use disorders NIAAA: 3 question screen Trauma: PC-PTSD: Primary Care- Post Traumatic Stress Disorder (for veterans) PCL-C: Abbreviated PTSD Checklist, Civilian Version Suicide or Nursing Assessment for Suicide/Violence (4 questions) Violence: If appropriate, followed by: Suicide Assessment (23 questions) Violence Assessment (23 questions) BH Works: BH Works, a tablet-based screening IT solution has a “smart” assessment tool which covers 13 domains of behavioral health. SBIRT: Screening, Brief Intervention and Referral to Treatment is an evidence based practice.
    [Show full text]
  • Substance Use Disorders (SUD) Begin in Childhood Or Adolescence (Kandel, 1992)
    PSYCHIATRY TELEHEALTH, LIAISON & CONSULTS (PSYCH TLC) Substance Related Disorders in Children and Adolescents Written and initially reviewed, 11/2011: Zaid Malik, M.D. Deepmala Deepmala, M.D Jody Brown, M.D. Laurence Miller, M.D. Reviewed and updated, 03/04/2014: Deepmala Deepmala, M.D. Work submitted by Contract # 4600016732 from the Division of Medical Services, Arkansas Department of Human Services 1 | P a g e Department of Human Services Psych TLC Phone Numbers: 501-526-7425 or 1-866-273-3835 The free Child Psychiatry Telemedicine, Liaison & Consult (Psych TLC) service is available for: Consultation on psychiatric medication related issues including: . Advice on initial management for your patient . Titration of psychiatric medications . Side effects of psychiatric medications . Combination of psychiatric medications with other medications Consultation regarding children with mental health related issues Psychiatric evaluations in special cases via tele-video Educational opportunities This service is free to all Arkansas physicians caring for children. Telephone consults are made within 15 minutes of placing the call and can be accomplished while the child and/or parent are still in the office. Arkansas Division of Behavioral Health Services (DBHS): (501) 686-9465 http://humanservices.arkansas.gov/dbhs/Pages/default.aspx 2 | P a g e Substance Related Disorders in Children and Adolescents ______________________________________________________ Table of Contents 1. Epidemiology 2. Symptomatology 3. Diagnostic Criteria -- Highlights of Changes from DSM IV to DSM 5 3.1 Substance Use Disorder 3.2 Substance Induced Disorder 3.2.1 Substance Withdrawal 3.2.2 Substance Intoxication 3.2.3 Substance/Medication-Induced Mental Disorders 4. Etiology, Risk Factors and Protective Factors 4.1 Etiology 4.2 Risk Factors and Protective Factors 5.
    [Show full text]
  • Opioid Overdose TOOLKIT: Information for Prescribers TABLE of CONTENTS
    S A M H S A Opioid Overdose TOOLKIT: Information for Prescribers TABLE OF CONTENTS INFORMATION FOR PRESCRIBERS OPIOID OVERDOSE 3 TREATING OPIOID OVERDOSE 7 LEGAL AND LIABILITY CONSIDERATIONS 9 CLAIMS CODING AND BILLING 9 RESOURCES FOR PRESCRIBERS 9 ACKNOWLEDGMENTS, ETC. 11 n Acknowledgments n Disclaimer n Public Domain Notice n Electronic Access and Copies of Publication n Recommended Citation n Originating Office Also see the other components of this Toolkit: . Facts for Community Members . Five Essential Steps for First Responders . Safety Advice for Patients & Family Members . Recovering from Opioid Overdose: Resources for Overdose Survivors & Family Members INFORMATION FOR PRESCRIBERS pioid overdose is a major public health problem, accounting for TAKE SPECIAL PRECAUTIONS almost 17,000 deaths a year in the United States [1]. Overdose WITH NEW PATIENTS. Many experts Oinvolves both males and females of all ages, ethnicities, and recommend that additional precautions demographic and economic characteristics, and involves both illicit be taken in prescribing for new patients opioids such as heroin and, increasingly, prescription opioid analgesics [5,6]. These might involve the following: such as oxycodone, hydrocodone, fentanyl and methadone [2]. 1. Assessment: In addition to the patient Physicians and other health care providers can make a major history and examination, the physi- contribution toward reducing the toll of opioid overdose through the cian should determine who has been care they take in prescribing opioid analgesics and
    [Show full text]
  • Cage Questionnaire Stand For
    Cage Questionnaire Stand For Cachectical Georges misgiven matrilineally, he interflows his akaryotes very outstandingly. Shelden remains unlockable after Jud outeating compendiously or outdrove any conclusions. Bryon often abating ava when painted Anatollo foozle closest and pickaxes her borecole. Kelly et al, sign that process is as it was also identified by pdg can lead to report provides cues for informational purposes was as interruptthe flow of questionnaire stand for perception of information that Warning Signs of Alcoholism What this Look For QuitAlcohol. ADOLESCENT ALCOHOL AND heal USE high ABUSE. He served as the founding director of the Bowles Center for Alcohol Studies where he developed the lace questionnaire and view Dr John A Ewing's. What questions are asked in between CAGE questionnaire? Appendix H AUDIT USAlcohol Use Disorders Identification Test. How to run and Score with FAST Alcohol Screening Test. SBIRT SAMHSA. Who created the nutrition questionnaire? Format A 10-item screening questionnaire with 3 questions on. Demonstrated to celebrate better screening properties than CAGE CRAFFT or. CAGE the is a widely used and an extensively validated method of screening for alcoholism Two yes responses indicate below the possibility of. Tribal Healing to Wellness Courts. PDF Screening for Alcohol Abuse Using the CAGE. CAGE Questionnaire Maelstrom research. Behavioral Health Screeners. However their performance as standalone tools is uncertain and further. Yes 1 No 0 I need to need with my hands to stand separate from a chair who is poor sign of weak leg muscles. The member a principal brief screen is probably lost most widely used and promoted for.
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]
  • SAMHSA Opioid Overdose Prevention TOOLKIT
    SAMHSA Opioid Overdose Prevention TOOLKIT Opioid Use Disorder Facts Five Essential Steps for First Responders Information for Prescribers Safety Advice for Patients & Family Members Recovering From Opioid Overdose TABLE OF CONTENTS SAMHSA Opioid Overdose Prevention Toolkit Opioid Use Disorder Facts.................................................................................................................. 1 Scope of the Problem....................................................................................................................... 1 Strategies to Prevent Overdose Deaths.......................................................................................... 2 Resources for Communities............................................................................................................. 4 Five Essential Steps for First Responders ........................................................................................ 5 Step 1: Evaluate for Signs of Opioid Overdose ................................................................................ 5 Step 2: Call 911 for Help .................................................................................................................. 5 Step 3: Administer Naloxone ............................................................................................................ 6 Step 4: Support the Person’s Breathing ........................................................................................... 7 Step 5: Monitor the Person’s Response ..........................................................................................
    [Show full text]
  • International Standards for the Treatment of Drug Use Disorders — Draft for Field Testing
    E/CN.7/2016/CRP.4 11 March 2016 English only Commission on Narcotic Drugs Fifty-ninth session Vienna, 14-22 March 2016 Item 9 of the provisional agenda* Preparations for the special session of the General Assembly on the world drug problem to be held in 2016 International Standards for the Treatment of Drug Use Disorders — Draft for Field Testing The International Standards for the Treatment of Drug Use Disorders (Standards) were prepared by UNODC and WHO to support Member States in the development and expansion of treatment services that offer effective and ethical treatment. The goal of such treatment is to reverse the negative impact that persisting drug use disorders have on the individual and to help them achieve as full recovery from the disorder as possible and to become a productive member of their society. The Standards were developed in the framework of the UNODC-WHO Programme on Drug Dependence Treatment and Care and are built on existing publications. They provide United Nations Member States with a practical and comprehensive technical tool that will help to guide policy development; plan, organize and manage drug treatment services within and beyond the health system; develop the capacity of human resources; and evaluate service and system level interventions. The Standards will be made available to the Commission for its consideration at its fifty- ninth session. __________________ * E/CN.7/2016/1. V.16-01463 (E) *1601463* INTERNATIONAL STANDARDS FOR THE TREATMENT OF DRUG USE DISORDERS DRAFT FOR FIELD TESTING March 2016 Acknowledgements The United Nations Office on Drugs and Crime (UNODC) would like to acknowledge the following for their invaluable contribution to the process of publication of these standards: The group of international experts for providing the relevant scientific evidence, technical advice and developing the main draft of the standards, including (in alphabetical order): Dr.
    [Show full text]
  • Chapter 2 Medication- Assisted Treatment
    CHAPTER 2 MEDICATION- ASSISTED TREATMENT Authors: Stephenson, D. (2.1 Methadone) Ling, W.; Shoptaw, S.; Torrington, M. (2.2 Buprenorphine) Saxon, A. (2.3 Naltrexone) 2.1 METHADONE 2.1.1. Introduction to Methadone hours in most patients. Methadone undergoes extensive Treatment first-pass metabolism in the liver. It binds to albumin and other proteins in the lung, kidney, liver and spleen. Tissue stores in these areas build up over time, and there is a Clarification of terms gradual equilibration between tissue stores and methadone in circulation. This buildup of tissue levels produces daily increases in the medication’s impact on the patient until California and Federal Regulations regarding methadone steady state is reached, which takes about 5 days. use the term Opioid Addiction to refer to the condition that is listed in the DSM-5 as Opioid Use Disorder (OUD). Methadone’s unique pharmacologic properties make it highly effective for management of OUD. The slow onset of action Methadone: description, Properties & means that there is no rush after ingestion. The long half-life means that craving diminishes and symptoms of withdrawal Black Box Warning do not emerge between doses, ending the cycling between being sick, intoxicated and normal and decreasing craving. Methadone is a synthetic opioid that can be taken orally and acts as a full agonist at the mu receptor. It is available However, the long half-life also means that any given dose in liquid or tablet form. In California, OTPs are required to of methadone will produce a higher blood level each day use the liquid formulation.
    [Show full text]
  • Using Rating Scales in a Clinical Setting: a Guide for Psychiatrists
    Web audio at CurrentPsychiatry.com Dr. Gupta discusses how he uses behavioral health rating scales in his clinical practice Using rating scales in a clinical setting: A guide for psychiatrists Consider these brief, easy-to-use behavioral health rating scales to guide diagnosis, monitor care n the current health care environment, there is an increas- ing demand for objective assessment of disease states.1 IThis is particularly apparent in psychiatry, where docu- mentation of outcomes lags that of other areas of medicine. In 2012, the additional health care costs incurred by per- sons with mental health diagnoses were estimated to be $293 billion among commercially insured, Medicaid, and Medicare beneficiaries in the United States—a figure that is 273% higher than the cost for those without psychiatric diag- noses.2 Psychiatric and medical illnesses can be so tightly linked that accurate diagnosis and treatment of psychiatric disorders becomes essential to control medical illnesses. It is not surprising that there is increased scrutiny to the ways FRESNO BEE/CONTRIBUTOR in which psychiatric care can be objectively assessed and monitored, and payers such as Centers for Medicare and Julie M. Wood, PhD Medicaid Services (CMS) increasingly require objective doc- Consultant Medical Liaison, Neuroscience umentation of disease state improvement for payment.3 Lilly USA, LLC Indianapolis, Indiana Support for objective assessment of disease derives from the collaborative care model. This model is designed Sanjay Gupta, MD Clinical Professor to better integrate psychiatric and primary care by Departments of Psychiatry (among other practices) establishing the Patient-Centered SUNY Upstate Medical University Medical Home and emphasizing screening and monitor- Syracuse, New York SUNY Buffalo School of Medicine and Biomedical Sciences ing patient-reported outcomes over time to assess treat- Buffalo, New York 4 ment response.
    [Show full text]
  • Substance Induced Disorders
    Substance Induced Disorders Julie Kmiec, DO University of Pittsburgh AOAAM 2018 Objectives At the end of this lecture, participants should be able to: ❖Understand the difference between substance induced disorders and independent psychiatric disorders ❖Be able to diagnose substance induced disorder versus independent mood, anxiety, or psychotic disorder ❖Discuss typical treatment for independent psychiatric disorders ❖Understand the importance of differentiating between substance-induced and independent psychiatric disorders List of Substances in DSM ❖Alcohol ❖Caffeine ❖Cannabis ❖Hallucinogens (ecstasy, LSD, PCP, mescaline, etc) ❖Inhalants ❖Opioids ❖Sedatives, hypnotics, and anxiolytics ❖Stimulants (amphetamines, cocaine, and other stimulants) ❖Tobacco ❖Other (or unknown) substances DSM-5, 2013 DIAGNOSES ASSOCIATED WITH CLASS OF SUBSTANCE Substance Anxiety Depress Bipolar Psychotic OC Neuroco Sleep Delirium Sexual gnitive alcohol I/W I/W I/W I/W I/W/P I/W I/W I/W cannabis I I I/W I hallucinogen I I I I I inhalant I I I I/P I opioid W I/W I/W I/W I/W sedative W I/W I/W I/W I/W/P I/W I/W I/W stimulant I/W I/W I/W W I/W I/W I I caffeine I I/W tobacco W Onset during I = intoxication; W = withdrawal P = persisting DSM-5, 2013 DIAGNOSES ASSOCIATED WITH CLASS OF SUBSTANCE Substance SUD Intoxication Withdrawal alcohol X X X cannabis X X X hallucinogen X X inhalant X X opioid X X X sedative X X X stimulant X X X caffeine X X tobacco X X DSM-5, 2013 Diagnosis ❖Difficult to diagnose psychiatric disorders when someone actively using substance ❖Symptoms
    [Show full text]